Forsta AP Fonden Acquires 2,900 Shares of Humana Inc. (NYSE:HUM)

Forsta AP Fonden increased its stake in Humana Inc. (NYSE:HUM) by 13.3% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 24,700 shares of the insurance provider’s stock after acquiring an additional 2,900 shares during the quarter. Forsta AP Fonden’s holdings in Humana were worth $7,823,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of HUM. Swedbank AB increased its stake in Humana by 3.0% in the third quarter. Swedbank AB now owns 105,976 shares of the insurance provider’s stock valued at $33,567,000 after purchasing an additional 3,085 shares in the last quarter. Heritage Oak Wealth Advisors LLC bought a new stake in Humana in the 2nd quarter valued at about $3,456,000. Mandatum Life Insurance Co Ltd raised its stake in Humana by 115.4% during the 3rd quarter. Mandatum Life Insurance Co Ltd now owns 14,000 shares of the insurance provider’s stock worth $4,434,000 after buying an additional 7,500 shares during the period. APG Asset Management US Inc. boosted its holdings in Humana by 3.0% in the second quarter. APG Asset Management US Inc. now owns 67,669 shares of the insurance provider’s stock worth $25,274,000 after acquiring an additional 1,955 shares in the last quarter. Finally, Sei Investments Co. boosted its holdings in Humana by 0.4% in the first quarter. Sei Investments Co. now owns 61,897 shares of the insurance provider’s stock worth $21,462,000 after acquiring an additional 264 shares in the last quarter. Institutional investors and hedge funds own 92.38% of the company’s stock.

Humana Stock Performance

Shares of HUM stock opened at $260.73 on Monday. Humana Inc. has a 52 week low of $213.31 and a 52 week high of $527.18. The firm’s 50-day simple moving average is $306.51 and its two-hundred day simple moving average is $336.35. The firm has a market cap of $31.39 billion, a price-to-earnings ratio of 18.60, a P/E/G ratio of 2.04 and a beta of 0.50. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.66 and a current ratio of 1.66.

Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, July 31st. The insurance provider reported $6.96 EPS for the quarter, beating the consensus estimate of $5.89 by $1.07. The business had revenue of $29.54 billion for the quarter, compared to the consensus estimate of $28.52 billion. Humana had a return on equity of 16.12% and a net margin of 1.53%. Humana’s revenue for the quarter was up 10.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $8.94 earnings per share. As a group, equities analysts forecast that Humana Inc. will post 16.06 earnings per share for the current year.

Humana Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be paid a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a yield of 1.36%. The ex-dividend date is Tuesday, December 31st. Humana’s dividend payout ratio is currently 25.25%.

Wall Street Analyst Weigh In

HUM has been the topic of a number of research reports. TD Cowen lowered Humana from a “buy” rating to a “hold” rating and lowered their target price for the stock from $402.00 to $261.00 in a research report on Monday, October 7th. Sanford C. Bernstein upgraded shares of Humana from a “market perform” rating to an “outperform” rating and set a $308.00 price objective on the stock in a report on Tuesday, October 8th. Truist Financial reduced their price objective on shares of Humana from $400.00 to $260.00 and set a “hold” rating for the company in a report on Friday, October 11th. Leerink Partnrs lowered shares of Humana from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 2nd. Finally, Oppenheimer cut their price target on Humana from $400.00 to $280.00 and set an “outperform” rating for the company in a research note on Thursday, October 3rd. One analyst has rated the stock with a sell rating, nineteen have issued a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $315.33.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.